

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): September 27, 2010**

---

**ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-32085**  
(Commission  
File Number)

**36-4392754**  
(IRS Employer  
Identification No.)

**222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654**  
(Address of Principal Executive Offices) (Zip Code)

**Registrant's Telephone Number, Including Area Code: (312) 506-1200**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 7.01. Regulation FD Disclosure.**

Attached as Exhibit 99.1 hereto is an Investor Presentation dated September 2010, which is incorporated herein by reference.

The information contained in, or incorporated into, this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

**Item 9.01 Financial Statements, *Pro Forma* Financial Information and Exhibits.**

*(d) Exhibits.*

Exhibit No.

Exhibit 99.1 Investor Presentation dated September 2010

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: September 27, 2010

By: \_\_\_\_\_ /s/ WILLIAM J. DAVIS  
William J. Davis  
Chief Financial Officer

---

**EXHIBIT INDEX**

**Exhibit No.**

Exhibit 99.1      Investor Presentation dated September 2010

A Connected  
Community  
of Health™

**Investor Presentation  
September 2010**



# Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements regarding future events or developments, our future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements with the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition. Such risks, uncertainties and other factors include, among other things: the possibility that the expected synergies, efficiencies and cost savings of the merger with Eclipsys Corporation ("Eclipsys") will not be realized, or will not be realized within the expected time period; potential difficulties or delays in achieving platform and product integration and the connection and movement of data among hospitals, physicians, patients and others; the risk that the Allscripts and Eclipsys businesses will not be integrated successfully; competition within the industries in which we operate; failure to achieve certification under the Health Information Technology for Economic and Clinical Health Act could result in increased development costs, a breach of some customer obligations and could put us at a competitive disadvantage in the marketplace; the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; the outcome of any legal proceeding that has been or may be instituted against us; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology; and breach of our security by third parties. See our Annual Report on Form 10-K for the fiscal year ended May 31, 2010 and other public filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.

To be the most trusted provider of innovative solutions that empower all stakeholders across the healthcare continuum to deliver world-class outcomes.

Our Mission



# Allscripts Corporate Snapshot



## Our Clients

- 180,000 Providers
- 150,000 Physician Practices
- 1,500 Hospitals
- 10,000 Post Acute Facilities
- 27,000 Clinicians In Patients' Homes Every Day



## Our Company

- 5,500 Employees
- \$1.2BB LTM Pro Forma Revenue
- Facilities in 24 States, Canada, India, the Middle East and The Philippines
- 1 Complete Set of Solutions



# Investment Highlights

- > Leading healthcare IT company with the broadest set of capabilities across every venue of care including physicians, hospitals, post-acute and homecare
- > The most utilized clinical solutions enabling health care providers to fully capitalize on the \$30BB federal stimulus program
- > Leadership in technology and innovation uniquely positions Allscripts to aggressively compete for the \$43BB healthcare IT solutions market
- > A highly attractive financial profile with high recurring revenue, significant operating leverage and cost synergy opportunities and strong free cash flow
- > Proven and experienced “industrial strength” management team

# The Time is NOW

## A National Problem

- Quality Issues
- Medical Errors / Safety Concerns
- Rising Cost
- Significant Waste



## A Market that is Ready

- \$43BB Opportunity
- \$30BB in Stimulus Funding
- ~15% Penetration in Physician Practices
- Rise of the Employed Physicians
- Hospitals Driving Adoption



## A Significant Opportunity

We are at the *beginning* of what we expect will be the single fastest transformation of any industry in US history

# Addressing the Entire Market Opportunity

Acute/Ambulatory EHR Opportunity 2010-2014 = ~\$43BB



Source: McKinsey & Company


**Well positioned to aggressively compete in the \$16BB (~35%) integrated market**

# Ambulatory Market Potential

Practice Size	Total # of Practices	EHR Penetration (FY09/10)
1-3 Physicians	163,000	~13%
4-9 Physician	27,000	~22%
10-25 Physicians	8,000	~33%
26+ Physicians	2,000	~50%
<b>Total</b>	<b>200,000</b>	<b>~15%</b>

Source: SK&A = SK&A Information Services which sells databases for sales and marketing success in healthcare industry

# Increased Certainty for Widespread EHR Adoption



Source: National Center for Health Statistics

(1) ~20% estimate based on number of ambulatory physicians; penetration as a percentage of number of physician practices is ~11%

(2) Hospitals >200 beds

# Allscripts: Competitive Differentiation

## One Network.

The largest connected network in the nation... and in your community.

- The Largest Network with a Client Base of 180,000 Physicians, 1,500 Hospitals and 10,000 Post Acute Care Providers
- The Unique Ability to Truly Connect a Community

## One Platform.

Open, flexible, and innovative to help you connect inside and outside your organization.


- Comprehensive, Integrated Solutions for all Settings
- Rapid Implementation Approach to Attain "Meaningful Use"
- A Track Record of Innovation with a 'Future State' Clinical/Financial Informatics Capability
- Common Microsoft platform and a shared 'open architecture' approach, simplifying the connection to third-party applications across every care setting

## One Patient.

A complete portfolio that delivers a single patient record across your community.

- One Patient Record Across an Organization and the Community – One Source of Truth

# One Network: The Largest Community in the Nation



-  Hospitals
-  Physician Practices
-  Post Acute Facilities & Agencies


- **The 'Hub':** Over 1,500 Hospitals including 40% of "America's Best Hospitals" as Clients
- **The 'Spokes':** Over 180,000 MDs and 10,000 Post Acute Care Organizations are Connected to other Practices, Patients, Pharmacies, Payors, Clinical Labs and Hospitals

# One Platform: A Complete, Integrated Solutions Portfolio

	Clinical	Financial	Administrative	Analytics	Services
Ambulatory Solutions	Electronic Health Record			CQS	Management Consulting
	Payerpath			Analytics	Academy Education
	ePrescribe				Ready
	Practice Management				
Acute Solutions (Sunrise)	Clinical Manager	Patient Financials	Access Management	EPSi	Outsourcing
	Acute Care	Financial Manager	Record Manager	Patient Flow	Remote Hosting
	Emergency Care		Enterprise Identifier	Clinical Analytics	Consulting
	Pharmacy				Network & Desktop
	Laboratory				Education
	Knowledge-Based Charting				Implementation
	Acute Content				Identity & Eligibility
	Knowledge-Based Medication Administration				
	Radiology				
	Care Management				
Post-Acute Solutions	Homecare / Hospice				
				Referral Management	
Community Solutions	Community Exchange				
	Community Record				
	Helios				



# One Patient: Critical Patient Data Flows Freely



# Proven Management Team

Executive	Position	Experience
Glen Tullman	CEO	30+ Yrs
Phil Pead	Chairman	30+ Yrs
Lee Shapiro	President	30+ Yrs
Eileen McPartland	COO	25+ Yrs
Bill Davis	CFO	19+ Yrs
Jeff Surges	President, Sales	20+ Yrs
Laurie McGraw	Chief Client Officer	20+ Yrs
John Gomez	President, Product Strategy & Development	25+ Yrs
Diane Adams	EVP, Culture and Talent	20+ Yrs
Kent Alexander	General Counsel	25+ Yrs

**Management team with a track record of operational execution, strong financial performance, integrating acquisitions and driving shareholder value**

# Financial Highlights

## Significant Growth

- Allscripts LTM bookings of \$415MM, up 24% year-over-year
- Eclipsys YTD 2010 bookings of \$259MM illustrates market momentum
- Allscripts FY2010 non-GAAP net income of \$98MM, up 28%
- Eclipsys 1H'10 non-GAAP net income of \$20MM, up 8% year-over-year
- ARRA stimulus program creates long-tailed demand curve

## Revenue Visibility

- High recurring revenue model
- Investments (e.g., READY, Upgrade Enablement Center, Sunrise 5.5, Helios) accelerate implementations
- Large, diverse client base


## Operating Leverage

- Total R&D investments of ~\$70MM and ~\$84MM by Allscripts & Eclipsys, respectively
- Significant benefits from Project DRIVE initiatives
- Allscripts Distribution Network
- Strong free cash flow


Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at <http://investor.allscripts.com>

# Pro Forma Performance

**Combined Non-GAAP Revenue**  
**CY 2009<sup>(1)</sup> Non-GAAP Revenue: \$1,188MM**



**1H 2010 Non-GAAP Revenue: \$634MM**



**Combined Non-GAAP Net Income (\$millions)**



Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at <http://investor.allscripts.com>


(1) Allscripts calendar year assumes a November year end.

# Significant Key Cost Synergies

## Key Cost Synergy Drivers

- Duplicate management structure
- Duplicate public company costs
- Duplicate backend office and system integration
- Marketing

Projected Cost Synergies Over Three Years





# 2-3 Year Pro Forma Financial Outlook

		Comments
<b>Revenue Growth</b>	<b>8-10% +</b>	<ul style="list-style-type: none"> <li>• Similar to Allscripts standalone revenue growth outlook</li> </ul>
<b>Non-GAAP Operating Margin</b>	<b>20% +</b>	<ul style="list-style-type: none"> <li>• Eclipsys margins historically lower than Allscripts margins</li> <li>• Cost synergies improve combined margins back towards near Allscripts historical margins</li> </ul>
<b>Non-GAAP EPS Growth</b>	<b>15-18% +</b>	<ul style="list-style-type: none"> <li>• Reflects new capital structure</li> <li>• Reflects only cost synergies</li> </ul>

Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at <http://investor.allscripts.com>

# Strong Pro Forma Free Cash Flow Generation

## Pro Forma Capitalization 5/31/10

<b>Capitalization</b>	<b>Allscripts<sup>(1)</sup></b>	<b>Eclipsys<sup>(2)</sup></b>	<b>Adj.<sup>(3)</sup></b>	<b>Pro forma</b>
Cash & Marketable Securities	\$143	\$178	(\$173)	\$148
New Revolver (\$250mm)	–	–	100	100
New Term Loan	–	–	470	470
<b>Total Debt</b>	<b>–</b>	<b>–</b>	<b>\$570</b>	<b>\$570</b>
<b>Equity<sup>(4)</sup></b>	<b>807</b>	<b>458</b>	<b>35</b>	<b>1,300</b>
<b>Total Capitalization</b>	<b>\$807</b>	<b>\$458</b>	<b>\$605</b>	<b>\$1,870</b>
<b>Credit Statistics</b>				
LTM EBITDA <sup>(1)(2)(5)</sup>	\$176	\$96		\$272
Total Debt / LTM EBITDA <sup>(1)(2)(5)</sup>	–	–		2.1x
Debt / Capitalization	–	–		30.5%

1 Allscripts balance sheet and EBITDA for the year ended 5/31/10.

2 Eclipsys balance sheet and EBITDA for the period ended and last twelve months ending 6/30/10, respectively. Cash and marketable securities excludes restricted cash and includes \$35MM of proceeds from the sale of Auction Rate Securities in August 2010.

3 Cash adjustment includes a) \$55MM of one-time banking, legal, and other professional fees and expenses related to the merger with Eclipsys, b) \$100MM payment associated with Misys' put option, c) \$9MM of \$119MM premiums paid to Misys out of combined cash. Cash adjustments exclude future retention and non-recurring compensation expenses and synergy realization costs expected to be incurred over the first 2 years post-closing.

4 Pro forma equity adjusted for a) \$33MM of upfront fees & expenses and one-time costs, b) \$460MM share repurchase, c) merger with Eclipsys reflecting 59.6MM Eclipsys shares at a \$20.22 implied offer price based on closing prices on 8/6/10 and a 1.2 exchange ratio, d) Misys's \$100MM put and \$2MM additional premium.

5 EBITDA is calculated as net income plus income tax expense, interest expense, stock-based compensation expense, depreciation & amortization, deferred revenue adjustments, certain one-time and transaction-related expenses, and non-recurring losses on the sale of investments minus non-recurring gains on the sale of assets.

Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at <http://investor.allscripts.com>.



One Network.  
One Platform.  
One Patient.



# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the twelve months ended May 31, 2010.

	<b>Allscripts</b>
	<b>Twelve Months Ended</b>
	<b>May 31, 2010</b>
<b>Net income, as reported</b>	62.9
Deferred revenue adjustment	5.1
Acquisition-related amortization	22.7
Stock-based compensation expense	14.8
Transaction-related expense	14.4
Non-GAAP adjustments tax effected at 39%	(22.1)
Tax rate alignment	0.4
<b>Total non-GAAP net income</b>	<b>98.2</b>

# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the six months ended June 30, 2010.

	Eclipsys
	Six Months Ended
	June 30, 2010
<b>Net income, as reported</b>	7.0
Acquisition-related amortization	3.7
Stock-based compensation expense	6.3
Transaction-related expense	2.0
ARS sales	0.9
<b>Total non-GAAP net income</b>	19.9

# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue reconciliation for the twelve months ended November 30, 2009 (Allscripts) and twelve months ended December 31, 2009 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Twelve Months Ended		
	November 30, 2009	December 31, 2009	
<b>Total revenue, as reported</b>	661.1	519.1	1,180.2
Deferred revenue adjustment	9.7	8.0	17.7
Elimination of prepackaged medications	(9.7)		(9.7)
<b>Total non-GAAP revenue</b>	<u>661.1</u>	<u>527.1</u>	<u>1,188.2</u>

# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue and net income reconciliation for the six months ended May 31, 2010 (Allscripts) and six months ended June 30, 2010 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Six Months Ended		
	May 31, 2010	June 30, 2010	
<b>Total revenue, as reported</b>	370.2	262.8	633.0
Deferred revenue adjustment	1.1	-	1.1
<b>Total non-GAAP revenue</b>	<u>371.3</u>	<u>262.8</u>	<u>634.1</u>
<b>Net income, as reported</b>	34.2	7.0	41.2
Deferred revenue adjustment	0.7	-	0.7
Acquisition-related amortization	7.0	3.7	10.8
Stock-based compensation expense	4.3	6.3	10.6
Transaction-related expense	5.7	2.0	7.7
ARS sales	-	0.9	0.9
Tax rate alignment	0.2	-	0.2
<b>Total non-GAAP net income</b>	<u>52.1</u>	<u>19.9</u>	<u>72.1</u>

# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the six months ended May 31, 2009 (Allscripts) and six months ended June 30, 2009 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Six Months Ended		
	May 31, 2009	June 30, 2009	
<b>Net income, as reported</b>	26.7	(5.0)	21.7
Deferred revenue adjustment	3.4	2.8	6.2
Acquisition-related amortization	6.9	3.9	10.8
Stock-based compensation expense	2.7	7.6	10.3
Transaction-related expense	6.2	-	6.2
Restructuring	-	5.3	5.3
Elimination of prepackaged medications	(0.7)	-	(0.7)
Tax related items	-	3.7	3.7
<b>Total non-GAAP net income</b>	<b>45.2</b>	<b>18.3</b>	<b>64.0</b>

# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the twelve months ended November 30, 2008 (Allscripts) and twelve months ended December 31, 2008 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Twelve Months Ended		
	November 30, 2008	December 31, 2008	
<b>Net income, as reported</b>	20.3	99.5	119.8
Deferred revenue adjustment	1.2	-	1.2
Acquisition-related amortization	9.4	4.8	14.2
Stock-based compensation expense	4.8	17.3	22.1
Transaction-related expense	22.7	-	22.7
AHS net income pre-Misys Healthcare merger	8.7	-	8.7
Professional services reorganization	-	1.4	1.4
Elimination of prepackaged medications	(1.9)	-	(1.9)
Non-recurring items	-	0.8	0.8
Valuation allowance	-	(80.0)	(80.0)
Headquarters Relocation	-	3.0	3.0
Derivative Litigation	-	1.3	1.3
Gain on sale of assets	-	(3.2)	(3.2)
In-process R&D charge	-	0.9	0.9
Tax related items	(0.9)	(4.0)	(4.9)
<b>Total non-GAAP net income</b>	<u>64.3</u>	<u>41.6</u>	<u>105.9</u>

# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the twelve months ended November 30, 2009 (Allscripts) and twelve months ended December 31, 2009 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Twelve Months Ended		
	November 30, 2009	December 31, 2009	
<b>Net income, as reported</b>	55.4	2.7	58.1
Deferred revenue adjustment	5.8	4.2	10.0
Acquisition-related amortization	13.9	7.7	21.6
Stock-based compensation expense	7.4	12.4	19.8
Transaction-related expense	9.4	-	9.4
Restructuring	-	6.0	6.0
ARS sales	-	0.7	0.7
Elimination of prepackaged medications	(0.7)	-	(0.7)
Tax related items	-	2.0	2.0
Tax rate alignment	0.3	0.7	1.0
<b>Total non-GAAP net income</b>	<u>91.5</u>	<u>36.4</u>	<u>127.9</u>



# Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP EBITDA reconciliation for the twelve months ended May 31, 2010 (Allscripts) and twelve months ended June 30, 2010 (Eclipsys).

	Allscripts	Eclipsys
	Twelve Months Ended	
	May 31, 2010	June 30, 2010
<b>Net income, as reported</b>	62.9	14.7
Taxes	40.7	11.4
Stock-based compensation expense	14.8	14.4
Depreciation and Amortization	36.0	51.8
Interest expense	2.0	1.9
Transaction-related expenses	14.4	-
Gain on Sale of Assets	5.1	2.3
Loss on Sale of Investments	-	(2.6)
Deferred revenue adjustment	-	2.5
<b>Earnings before interest, taxes, depreciation and amortization</b>	175.9	96.0

# Explanation of Non-GAAP Financial Measures

Allscripts hereby furnishes certain summary financial information regarding Allscripts and Eclipsys for the quarterly, annual and semi-annual periods set forth in this presentation. This summary financial information is not required by, or presented in accordance with, U.S. generally accepted accounting principles ("GAAP"), but supplements Allscripts' and Eclipsys' GAAP financial information by including adjustments that reflect the impact of divested or acquired operations, acquisition related deferred revenue and cost adjustments, transaction related expenses, stock-based compensation under SFAS No. 123R and other non-recurring income or expenses. The following non-GAAP performance measures are presented, together with a reconciliation to the corresponding summary GAAP financial information:

- **Non-GAAP revenue.** Non-GAAP revenue consists of GAAP revenue, excluding revenue related to certain divested operations and acquisition related deferred revenue adjustments, plus revenue related to acquired operations.
- **Non-GAAP operating income.** Non-GAAP operating income consists of GAAP operating income, excluding operating income related to certain divested operations, acquisition related deferred revenue and cost adjustments, acquisition-related amortization, stock-based compensation expense under SFAS No. 123R, transaction-related expenses and other non-recurring income or expenses, plus operating income related to acquired operations. **Non-GAAP operating margin** consists of non-GAAP operating income divided by non-GAAP revenue.
- **Non-GAAP net income.** Non-GAAP net income consists of GAAP net income, excluding net income related to certain divested operations, acquisition-related amortization, stock-based compensation expense under SFAS No. 123R, transaction-related expenses and other non-recurring income or expenses, plus income related to acquired operations, in each case net of any related tax benefit. The GAAP performance measures regarding Allscripts and Eclipsys were derived from their respective unaudited consolidated financial statements. **Non-GAAP EPS (earnings per share)** consists of non-GAAP net income divided by weighted-average shares outstanding used in computing diluted net income per share.

Allscripts has a fiscal year end as of May 31, and Eclipsys has a fiscal year end as of December 31. The non-GAAP summary quarterly information regarding Allscripts is presented for each of the quarters included in Allscripts' fiscal years ended May 31, 2010 and 2009, and six months ended May 31, 2008. The non-GAAP summary quarterly information regarding Eclipsys is presented for each of the quarters included in Eclipsys' six months ended June 30, 2010, year ended December 31, 2009 and year ended December 31, 2008.

The Non-GAAP summary quarterly information is also presented on a combined basis, which represents the combination of the quarterly information for Allscripts with the quarterly information for the nearest applicable fiscal quarter for Eclipsys. In reviewing this combined financial information, investors and potential investors should be aware that:

- no adjustment has been made to account for the fact that Eclipsys' fiscal quarters do not fully correspond to Allscripts' fiscal quarters;
- no adjustment has been made to account for any synergies or cost savings that may or are expected to occur as a result of the Merger;
- no adjustment has been made to account for any non-cash charges that Allscripts may incur in connection with the Merger;
- the non-GAAP financial information is provided for informational purposes only and does not purport to represent what the combined company's actual performance would have been had the Merger occurred prior to the periods indicated, and does not purport to indicate results of operations for any future period;
- the non-GAAP financial information does not include any pro forma assumptions or adjustments and should not be used as a substitute for financial statements prepared in accordance with U.S. GAAP. Allscripts' management believes that these summary non-GAAP performance measures provide useful supplemental information to management and investors regarding the underlying performance of Allscripts' and Eclipsys' business operations and facilitates comparisons to their historical operating results. Note however, that the summary non-GAAP combined quarterly information and summary non-GAAP financial measures are performance measures only, and do not provide any measure of each company's cash flow or liquidity. The summary non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts' and Eclipsys' results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of summary non-GAAP financial measures with summary GAAP financial measures furnished herewith.